ROCKVILLE, Md., Sep 27, 2010 (BUSINESS WIRE) --
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company
will be participating in the following investor conferences in October
- The 9th Annual BIO Investor Forum
October 5, 2010
9:00 AM Pacific
presentation, which will include a discussion of the Company's
business activities, financial outlook and current news, will be
- The 17th Annual BioCentury/Thomson Reuters
Newsmakers in the Biotech Industry Conference
New York, NY.
Corporate Overview Presentation
[The presentation, which will include a discussion
of the Company's business activities, financial outlook and current
news, will be webcast live.]
Both webcasts will be accessible from the Emergent website www.emergentbiosolutions.com
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company focused on the
development, manufacture and commercialization of vaccines and antibody
therapies that assist the body's immune system to prevent or treat
disease. Emergent's marketed product, BioThrax(R) (Anthrax
Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and
Drug Administration for the prevention of anthrax infection. Emergent's
product pipeline targets infectious diseases and includes programs
focused on anthrax, tuberculosis, typhoid, flu and chlamydia. Additional
information may be found at www.emergentbiosolutions.com.
SOURCE: Emergent BioSolutions Inc.
Emergent BioSolutions Inc.
Robert G. Burrows
Vice President, Investor Relations
Vice President, Corporate Communications